The Valley Desk

Clinical trial reportAnnals of the rheumatic diseasesPublished

Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study

Read the publication ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Drexel University College of Medicine, Johnson & Johnson, with Drexel University linked by the institution reference. Affiliation source

Publication record

Type
Clinical trial report
Venue
Annals of the rheumatic diseases
Published
Subject terms
Humans; Arthritis, Psoriatic; Disease Progression; Antirheumatic Agents; Antibodies, Monoclonal; Treatment Outcome; Severity of Illness Index; Double-Blind Method; Adult; Middle Aged; Female; Male
PubMed ID
40962616
Added to directory
Source checked

Report a correction or request removal